Bulldog Investors’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Bulldog Investors’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-43,364	Closed	-$2.62K	–	245
2026 Q1	$2.62K	Sell	43,364 -86,900	-67%	-$9.2K	﹤0.01%	214
2025 Q4	$24.4K	Hold	130,264	–	–	0.01%	192
2025 Q3	$28.3K	Buy	130,264 +57,300	+79%	+$10.7K	0.01%	170
2025 Q2	$8.77K	Buy	+72,964	New	+$9.38K	﹤0.01%	165

Other funds holding DMAAR

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Bulldog Investors's DMAAR Position: Q2 2026 in Review

Bulldog Investors sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q2 2026, closing a stake of 43,364 shares — an estimated $2.62K sold.

Bulldog Investors first reported a position in DMAAR in Q2 2025 and held it in 4 quarters. The position peaked at $28.3K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

Bulldog Investors reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q2 2026 after selling out during the quarter.
Bulldog Investors sold 43,364 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $2.62K.
Bulldog Investors first reported a position in Drugs Made In America Acquisition Corp Rights in Q2 2025 and held it in 4 quarters.
Bulldog Investors's Drugs Made In America Acquisition Corp Rights position peaked at $28.3K in Q3 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Bulldog Investors's 13F filing for Q2 2026, filed 14 Aug 2026.